Zeltherva (galinpepimut-S) / SELLAS Life Sciences 
Welcome,         Profile    Billing    Logout  
 0 Diseases   6 Trials   6 Trials   141 News 


12»
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion, Trial completion date, Trial primary completion date, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Nov 18, 2024   
    P1,  N=10, Completed, 
    Active, not recruiting --> Completed | N=90 --> 26 Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2024 | Trial primary completion date: Jul 2025 --> Nov 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial primary completion date:  Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov) -  Aug 22, 2024   
    P1,  N=15, Active, not recruiting, 
    Unknown status --> Completed | Phase classification: PN/A --> P1/2 Trial primary completion date: May 2024 --> Dec 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Aug 8, 2024   
    P1,  N=10, Active, not recruiting, 
    Trial primary completion date: May 2024 --> Dec 2024 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment closed, Monotherapy:  REGAL: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov) -  Mar 26, 2024   
    P3,  N=126, Active, not recruiting, 
    Coadministration of galinpepimut-S and nivolumab demonstrated a tolerable toxicity profile and induced immune responses in a subset of patients as indicated by immunophenotyping and disease control rate of 30% at 8 weeks but initial response and survival benefit were limited which may be due to the small sample size. Recruiting --> Active, not recruiting
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment closed, Trial primary completion date:  Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov) -  Oct 25, 2023   
    P1,  N=15, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Aug 2, 2023   
    P1,  N=10, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Galinpepimut-S (Twitter) -  Jun 5, 2023   
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment open, Trial completion date, Trial primary completion date, Monotherapy:  REGAL: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov) -  Feb 1, 2023   
    P3,  N=140, Recruiting, 
    Exploratory analysis for efficacy yielded a promising 1-year PFS rate. Unknown status --> Recruiting | Trial completion date: Apr 2022 --> Mar 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment closed, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Nov 25, 2022   
    P1,  N=10, Active, not recruiting, 
    Unknown status --> Recruiting | Trial completion date: Apr 2022 --> Mar 2025 | Trial primary completion date: Dec 2021 --> Dec 2024 Recruiting --> Active, not recruiting
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment open, Trial completion date:  Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov) -  Sep 6, 2022   
    P1,  N=15, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) -  Feb 21, 2022   
    P1/2,  N=90, Active, not recruiting, 
    Early recognition of the condition and timely discontinuation of an immune checkpoint inhibitor is crucial for the neurological outcome. Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Nov 2022
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=10, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Nov 2022 Trial completion date: Jul 2021 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2023
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Journal:  Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia. (Pubmed Central) -  Jul 9, 2021   
    GPS has been shown to be safe and tolerable in phase 1 and phase 2 studies and is now being evaluated in a phase 3 study.Expert opinion: Given the unmet need in the treatment of relapsed and refractory AML, especially among the elderly and patients with comorbidities who are not fit enough to undergo traditional salvage treatments, GPS could potentially fill the gap for this subset of patients. Future clinical trials utilizing GPS in second complete remission 2 (CR2) compared to best available therapy in AML and in combination with other immunotherapeutic agents (like pembrolizumab) for treatment for various malignancies are underway.
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, Trial primary completion date, Metastases:  Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) -  Mar 17, 2021   
    P1/2,  N=90, Recruiting, 
    Future clinical trials utilizing GPS in second complete remission 2 (CR2) compared to best available therapy in AML and in combination with other immunotherapeutic agents (like pembrolizumab) for treatment for various malignancies are underway. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2020 --> Jan 2024
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, BRCA Biomarker, PD(L)-1 Biomarker, Metastases:  Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) -  Nov 19, 2020   
    P1/2,  N=90, Recruiting, 
    Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2020 --> Jan 2024 Trial completion date: Jul 2021 --> Apr 2023
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) -  Sep 3, 2020   
    P1,  N=10, Recruiting, 
    Trial completion date: Jul 2021 --> Apr 2023 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021